{"id":"W2969712092","doi":"10.1016/j.eururo.2019.07.048","title":"First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Hospital; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba; University of Calgary","funders":"National Cancer Institute; Foundation Medicine; Pfizer Japan; Novartis Pharma; EMD Serono; Genentech; Ipsen; Alexion Pharmaceuticals; Eisai; National Comprehensive Cancer Network; Sanofi; Exelixis; GlaxoSmithKline; Astellas Pharma; Celldex Therapeutics; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Metastasis; Carcinoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004945465,0.0004271845,0.001558282,0.00181637,0.0003354422,0.001507811,0.001175085,0.0005727363,0.002159777],"category_scores_gemma":[0.01492814,0.000188748,0.001766851,0.005826218,0.0002497892,0.0006995948,0.001326773,0.0005805574,0.0004865828],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00169317,"about_ca_system_score_gemma":0.002311267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02264795,"about_ca_topic_score_gemma":0.02775603,"domain_scores_codex":[0.9930311,0.00233068,0.001212128,0.001072417,0.001978139,0.0003755517],"domain_scores_gemma":[0.9831275,0.004392689,0.008456982,0.001081157,0.00195126,0.0009904105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006558946,0.0002441469,0.9540237,0.001706881,0.003177439,0.00007485174,0.0001076297,0.001099725,0.0001705033,0.0001490478,0.01703125,0.01565592],"study_design_scores_gemma":[0.001561218,0.0004797586,0.9828218,0.000503881,0.002386753,0.0003519562,0.0002710419,0.001669152,0.0003039392,0.00008689158,0.009524834,0.00003885517],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7219353,0.0127807,0.0004547497,0.001089605,0.00005967464,0.000406211,0.2596422,0.00006036344,0.003571215],"genre_scores_gemma":[0.7882192,0.003015558,0.0006308315,0.0005367404,0.00006604402,0.0004504514,0.2066295,0.00003069745,0.0004209578],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02264795,"threshold_uncertainty_score":0.04503226,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03263677506092706,"score_gpt":0.2628622018563442,"score_spread":0.2302254267954172,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}